Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: Association with tumor progression

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 148-156

  Pietrowska, Monika ^a   Polańska, Joanna ^b   Suwiński, Rafał ^a   Wideł, Maciej ^a   Rutkowski, Tomasz ^a   Marczyk, Michał ^b   Domińczyk, Iwona ^a   Ponge, Lucyna ^a   Marczak, Łukasz ^c   Polański, Andrzej ^b,d   Widłak, Piotr ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^c INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^d POLISH JAPANESE INSTITUTE OF INFORMATION TECHNOLOGY   (Poland)

Author keywords

Cancer signatures; Mass spectrometry; Molecular classifiers; Pattern analysis; Serum proteomics

Indexed keywords

PEPTIDE; PROTEOME;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; COLON ADENOCARCINOMA; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEOMICS; SERUM; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84455171399     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1186     Document Type: Article

References (55)

1. Hanash S: Disease proteomics. Nature 422: 226-232, 2003.
2. Wulfkuhle JD, Liotta LA and Petricoin EF: Proteomic applications for the early detection of cancer. Nat Rev Cancer 3: 267-275, 2003.
3. Aebersold R and Mann M: Mass spectrometry-based proteomics. Nature 422: 198-207, 2003.
4. Liotta LA, Ferrari M and Petricoin EF: Clinical proteomics: written in blood. Nature 425: 905, 2003.
5. Palmblad M, Tiss A and Cramer R: Mass spectrometry in clinical proteomics - from the present to the future. Proteomics Clin Appl 3: 6-17, 2009.
6. Li L, Tang H, Wu Z, Gong J, Gruidl M, Zou J, Tockman M and Clark RA: Data mining techniques for cancer detection using serum proteomic profiling. Artif Intel Med 32: 71-83, 2004.
7. Conrads TP, Hood BL, Issaq HJ and Veenstra TD: Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool. Mol Diagn 8: 77-85, 2004.
8. Dworzanski JP and Snyder AP: Classification and identification of bacteria using mass spectrometry-based proteomics. Expert Rev Proteomics 2: 863-878, 2005.
9. Somorjai RL: Pattern recognition approaches for classifying proteomic mass spectra of biofluids. Methods Mol Biol 428: 383-396, 2008.
10. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC and Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577, 2002.
11. Posadas EM, Simpkins F, Liotta LA, MacDonald C and Kohn EC: Proteomic analysis for the early detection and rational treatment of cancer-realistic hope? Ann Oncol 16: 16-22, 2005.
12. Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G and Kohn EC: Proteomics in clinical trials and practice. Mol Cell Proteomics 5: 1819-1829, 2006.
13. Solassol J, Jacot W, Lhermitte L, Boulle N, Maudelonde T and Mangé A: Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics 3: 311-320, 2006.
14. Cho WC: Proteomics technologies and challenges. Genomics Proteomics Bioinformatics 5: 77-85, 2007.
15. Cho WC and Cheng CH: Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics 4: 401-410, 2007.
16. Hortin GL: The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52: 1223-1237, 2006.
17. Malle E, Sodin-Semrlb S and Kovacevica A: Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66: 9-26, 2009.
18. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument- Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI and Tempst P: Differential exoprotease activities confer tumorspecific serum peptidome patterns. J Clin Invest 116: 271-284, 2006.
19. Engwegen JY, Helgason HH, Cats A, Harris N, Bonfrer JMG, Schellens JHM and Beijnen JH: Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 12: 1536-1544, 2006.
20. Karpievitch YV, Hill EG, Smolka AJ, Morris JS, Coombes KR, Baggerly KA and Almeida JS: PrepMS: TOF MS Data Graphical Preprocessing Tool. Bioinformatics 23: 264-265, 2007.
21. Hilario M, Kalousis A, Pellegrini C and Müller M: Processing and classification of protein mass spectra. Mass Spectrometry Rev 25: 409-449, 2006.
22. Pietrowska M, Marczak Ł, Polańska J, Behrendt K, Nowicka E, Walaszczyk A, Chmura A, Deja R, Stobiecki M, Polański A , Tarnawski R and Widłak P: Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J Translat Med 7: e60, 2009.
23. Hastie T, Tibshirani R and Friedman JH: The Elements of Statistical Learning. Springer Verlag, 2001.
24. Schwarz GE: Estimating the dimension of a model. Ann Statistics 6: 461-464, 1978.
25. Lustgarten JL, Kimmel C, Ryberg H and Hogan W: EPO-KB: a searchable knowledge base of biomarker to protein links. Bioinformatics 24: 1418-1419, 2008.
26. Frank AM, Bandeira N, Shen Z, Tanner S, Briggs SP, Smith RD and Pevzner PA: Clustering millions of tandem mass spectra. J Proteome Res 7: 113-122, 2008.
27. Demissie M, Mascialino B, Calza S and Pawitan Y: Unequal group variances in microarray data analyses. Bioinformatics 24: 1168-1174, 2008.
28. Storey JD: A direct approach to false discovery rates. J Roy Statis Soc B 64: 79-49, 2002.
29. Vapnik V: The Nature of Statistical Learning Theory. Springer, 1995.
30. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JTC, Wang HM, Liao CT and Chen IH: Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 51: 2236-2244, 2004.
31. Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ and Koong AC: The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 10: 4806-4812, 2004.
32. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam B-L, Stack BC, Wright GL and Semmes OJ: Serum protein profiles to identify head and neck cancer. Clin Cancer Res 10: 1625-1632, 2004.
33. Wei Y-S, Zheng Y-H, Liang W-B, Zhang J-Z, Yang Z-H, Lv M-L, Jia J and Zhan L: Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer 112: 544-551, 2008.
34. Huang Y-J, Xuan C, Zhang B-B, Liao M, Deng K-F, He M and Zhao J-M: SELDI-TOF MS profiling of serum for detection of nasopharyngeal carcinoma. J Exp Clin Cancer Res 28: e85, 2009.
35. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJO, Johnson PJ and Martin A: Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94: 1898-1905, 2006.
36. Wang Q, Shen J, Li Z, Jie J, Wang W, Wang J, Zhang Z, Li Z, Yan L and Gu J: Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 9: e287, 2009.
37. Liu M, Li C-F, Chen H-S, Lin L-Q, Zhang C-P, Zhao J-L, Liu Y, Zhang S-J, Jin J-C, Wang L and Liu J-R: Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls. Proteome Sci 8: e16, 2010.
38. Liao CCL, Mehta A, Ward NJ, Marsh S, Arulampalam T and Norton JD: Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study. World J Surg Oncol 8: e33, 2010.
39. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC and Patz EF Jr: Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 3: 1720-1724, 2003.
40. Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J and He D: Development of proteomic patterns for detecting lung cancer. Dis Markers 19: 33-39, 2004.
41. Yang S, Xiao X, Zhang W, Zhang L, Zhang W, Zhou B, Chen G and He D: Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5: e83, 2005.
42. Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ and Wei ZJ: Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 31: 133-139, 2008.
43. Du J, Yang S, Lin X, Bu L, Nan Y, Huo S and Shang W: Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer Diagn Pathol 5: e60, 2010.
44. Cremona M, Calabro E, Randi G, De Bortoli M, Mondellini P, Verri C, Sozzi G, Pierotti MA, La Vecchia C, Pastorino U and Bongarzone I: Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. Cancer 116: 1326-1335, 2010.
45. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA and Flad T: Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84: 1220-1221, 2004.
46. Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE and Beijnen JH: Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 87: 161-172, 2007.
47. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV and Archakov AI: Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5: 3790-3797, 2005.
48. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, Abbruzzese JL and Kobayashi R: Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11: 1110-1118, 2005.
49. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA and Sadar MD: Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51: 695-707, 2005.
50. Li Y, Dang TA, Shen J, Perlaky L, Hicks J, Murray J, Meyer W, Chintagumpala M, Lau CC and Man TK: Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics 6: 3426-3435, 2006.
51. Combaret V, Bergeron C, Brejon S, Iacono I, Perol D, Negrier S and Puisieux A: Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett 228: 91-96, 2005.
52. Cho WC, Yip TT, Ngan RK, Yip TT, Podust VN, Yip C, Yiu HH, Yip V, Cheng WW, Ma VW and Law SC: ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin Chem 53: 241-250, 2007.
53. Roelofsen H, Alvarez-Llamas G, Dijkstra M, Breitling R, Havenga K, Bijzet J, Zandbergen W, De Vries MP, Ploeg RJ and Vonk RJ: Analyses of intricate kinetics of the serum proteome during and after colon surgery by protein expression time series. Proteomics 7: 3219-3228, 2007.
54. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, Liebler DC, Bigbee WL, Siegfried JM, Weissfeld JL, Gonzalez AL, Ninan M, Johnson DH, Carbone DP, Caprioli RM and Massion PP: Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J. Thorac Oncol 2: 893-901, 2007.
55. Cho WC, Yip TT, Cheng WW and Au JSK: Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer 102: 1731-1735, 2010.